UBS Suspends Coverage Of Valeant Over Lack of Transparency

UBS’ Marc Goodman suspended coverage of Valeant Pharmaceuticals Intl Inc VRX, citing lack of transparency in the company’s financials and uncertainty over the timeline of the visibility.

Analyst Marc Goodman believes that under these circumstances it is not practical to forecast the company’s financial results and maintain an investment opinion.